Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: A display panel, a method for driving the same, and a display apparatus are provided. The display panel includes a plurality of light-emitting elements. Each one of the light-emitting element is electrically connected to M pixel circuits, where M is a positive integer greater than or equal to 2. The M pixel circuits are configured to drive the light-emitting element to emit light respectively during different display phases of the display panel.

Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: The present disclosure provides a display panel, a method for driving the display panel, and a display apparatus. The display panel includes multiple pixel circuits. The pixel circuit includes a drive transistor and at least one switch unit. At least one switch unit includes M thin film transistors connected in parallel, and M is a positive integer greater than or equal to 2. The M thin film transistors are configured to be turned on during different display phases, respectively.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: A display panel has a display region and a frame region outside the display region. The display region includes a plurality of pixel circuits. The display panel includes a base substrate, a buffer layer, a semiconductor layer, a power signal layer, and an auxiliary circuit layer. The buffer layer is on a side of the base substrate. The buffer layer includes an a-Si layer. The semiconductor layer is on a side of the buffer layer away from the base substrate. The power signal layer is on a side of the semiconductor layer away from the base substrate. The power signal layer includes a plurality of first power voltage lines in the display region, and one first power voltage line of the plurality of first power voltage lines are electrically connected to a corresponding pixel circuit.

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

Abstract: An apparatus for forming a C1 to C5 oxygenate from carbon dioxide and a C1 to C4 hydrocarbon is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the C1 to C4 hydrocarbon and an outlet for the oxygenates. In one example the passageway includes therein a catalyst. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide in reacted with the C1 to C4 hydrocarbon in the generated plasma, thereby forming the oxygenates from at least some of the carbon dioxide and the C1 to C4 hydrocarbon. The DBD device comprises a conducting liquid as a ground electrode. A method and a use are also described.

Abstract: An apparatus for forming C1 to C5 alcohol, carboxylic acid, or mixture thereof from carbon dioxide and hydrogen is described. The apparatus comprises: a dielectric barrier discharge, DBD, device arranged to generate a plasma; and a passageway having an inlet for the carbon dioxide and the hydrogen and an outlet for the C1 to C5 alcohol, carboxylic acid, or mixture thereof and including therein a catalyst comprising nickel and/or cobalt and/or copper on a support. The passageway extends, at least in part, through the DBD device wherein, in use, the carbon dioxide is exposed to the catalyst in the presence of the hydrogen in the generated plasma, thereby forming the C1 to C5 alcohol, carboxylic acid, or mixture thereof from at least some of the carbon dioxide and the hydrogen. The DBD devices comprises a water electrode. A method and a catalyst are also described.

Abstract: A display panel and a display device are provided in the present disclosure. The display panel, having a display region and a frame region outside the display region, includes a base substrate; a buffer layer on a side of the base substrate, where the buffer layer includes an a-Si layer; a semiconductor layer on a side of the buffer layer away from the base substrate; an insulation layer on a side of the semiconductor layer away from the base substrate; and a power signal layer on a side of the insulation layer away from the base substrate. The power signal layer includes a plurality of first power voltage lines in the display region; and the power signal layer is electrically connected to a power signal terminal which alternately outputs a positive voltage signal and a negative voltage signal.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: The present disclosure provides a display panel, a method for driving the display panel, and a display apparatus. The display panel includes multiple pixel circuits. The pixel circuit includes a drive transistor and at least one switch unit. At least one switch unit includes M thin film transistors connected in parallel, and M is a positive integer greater than or equal to 2. The M thin film transistors are configured to be turned on during different display phases, respectively.

Abstract: A display panel, a method for driving the same, and a display apparatus are provided. The display panel includes a plurality of light-emitting elements. Each one of the light-emitting element is electrically connected to M pixel circuits, where M is a positive integer greater than or equal to 2. The M pixel circuits are configured to drive the light-emitting element to emit light respectively during different display phases of the display panel.

Abstract: A display panel and a display device are provided in the present disclosure. The display panel, having a display region and a frame region outside the display region, includes a base substrate; a buffer layer on a side of the base substrate, where the buffer layer includes an a-Si layer; a semiconductor layer on a side of the buffer layer away from the base substrate; an insulation layer on a side of the semiconductor layer away from the base substrate; and a power signal layer on a side of the insulation layer away from the base substrate. The power signal layer includes a plurality of first power voltage lines in the display region; and the power signal layer is electrically connected to a power signal terminal which alternately outputs a positive voltage signal and a negative voltage signal.

Abstract: An organic light emitting display panel and a display device are provided. The organic light emitting display panel includes: an anode power wire, the anode power wire including a first extension segment and a second extension segment, a head end of the first extension segment being electrically connected to the driving power supply, a tail end of the first extension segment being electrically connected to a head end of the second extension segment; each sub-pixel includes a light emitting device and two pixel driving circuits, anode connection terminals of the two pixel driving circuits are electrically connected to an anode of the light emitting device; anode power wire connection terminals of the two pixel driving circuits are electrically connected to the first extension segment and the second extension segment, respectively.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.